Could low-dose radiation boost immunotherapy for liver-limited colorectal cancer?

NCT ID NCT06848465

Recruiting now Disease control Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University Source: ClinicalTrials.gov ↗

First seen Apr 03, 2026 · Last updated May 15, 2026 · Updated 7 times

Summary

This early-phase study is testing whether adding low-dose radiotherapy to standard immunochemotherapy is safe and feasible for people with colorectal cancer that has spread only to the liver. About 9 to 18 adults aged 18-75 who have not had prior treatment will receive the combination therapy. The main goal is to check for side effects and see how well the treatment is tolerated.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Army Medical Center
RECRUITING

Chongqing, Chongqing Municipality, 400042, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
Daping Hospital, Army Medical University
ACTIVE_NOT_RECRUITING

Chongqing, Chongqing Municipality, 400042, China

Conditions

Explore the condition pages connected to this study.

COLORECTAL CANCER LDRT LIVER METASTASIS